On October 19, 2023, the official website of China's State Drug Administration showed that it approved the marketing application of Pfizer's LITFULO™ (Ritlecitinib) for the treatment of severe alopecia areata in adolescents over 12 years of age and adults.

It is a covalent JAK3/TEC double kinase inhibitor that is administered orally once a day at an approved dose of 50mg/ dose. The drug, which was approved by the FDA in June, is the first and only FDA-approved drug for the treatment of severe alopecia areata in adolescent patients (12 years and older).

Pre: 155 million dollars! Hengrui Medicine has another innovative drug to go to sea

Next: It can restore 80% hair growth, and Pfizer's new drug for alopecia areata was approved for sale in China, which can treat adolescent alopecia areata